The current unmet need in type 2 diabetes mellitus: Addressing glycemia and cardiovascular disease

Postgraduate Medicine

Volumn 121, Issue 3, 2009, Pages

  Levy, Philip ^a,b  

^a Phoenix Endocrinology Clinic   (United States)

^b NONE   (United States)

Author keywords

Antidiabetes; Bile acid sequestrant; Cardiovascular; Colesevelam HCl; Glycemic control; Type 2 diabetes mellitus

Indexed keywords

ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; ATORVASTATIN; COLESEVELAM; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; GLITAZONE DERIVATIVE; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEGLITINIDE; METFORMIN; MIGLITOL; NATEGLINIDE; PIOGLITAZONE; REPAGLINIDE; ROSIGLITAZONE; SIMVASTATIN; SITAGLIPTIN; SULFONYLUREA DERIVATIVE;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; DIET; DYSLIPIDEMIA; EXERCISE; GLYCEMIC CONTROL; HEALTH CARE NEED; HUMAN; HYPERTENSION; LIFESTYLE MODIFICATION; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; REVIEW; RISK FACTOR; RISK MANAGEMENT; SMOKING CESSATION; TREATMENT PLANNING; WEIGHT REDUCTION;

EID: 67649227935     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2009.05.suppl53.287     Document Type: Review

References (67)

1. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes(UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405-412. (Pubitemid 30609442)
2. Virally M, Blickle JF, Girard J, Halimi S, Simon D, Guillausseau PJ. Type 2 diabetes mellitus: epidemiology, pathophysiology, unmet needs and therapeutical perspectives. Diabetes Metab. 2007;33(4):231-244. (Pubitemid 47440080)
3. Centers for Disease Control and Prevention. National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2007. Atlanta, GA: US Department of Health and Human Services; 2008.
4. AACE Diabetes Mellitus Clinical Practice Guidelines Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract. 2007;13(suppl 1):1-68.
5. American Diabetes Association. Standards of medical care in diabetes - 2009. Diabetes Care. 2009;32(suppl 1):S13-S61.
6. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: update regarding thiazolidinediones: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2008;31(1):173-175.
7. Buse JB. Progressive use of medical therapies in type 2 diabetes. Diabetes Spectrum. 2000;13(4):211-220.
8. Bell DS. Current status of diabetes treatment. South Med J. 2002; 95(1):24-29. (Pubitemid 34131533)
9. Krentz AJ, Patel MB, Bailey CJ. New drugs for type 2 diabetes mellitus: what is their place in therapy? Drugs. 2008;68(15):2131-2162.
10. Precose (acarbose tablets) [package insert]. Wayne, NJ: Bayer Health-Care Pharmaceuticals, Inc; 2008.
11. Glyset (miglitol tablets) [package insert]. New York, NY: Pfizer Inc; 2008.
12. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA. 2003;290(4):486-494. (Pubitemid 37430502)
13. Glucophage (metformin hydrochloride tablets) [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2000.
14. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352(9131):854-865. (Pubitemid 28416719)
15. Welchol (colesevelam hydrochloride) [package insert]. Parsippany, NJ: Daiichi Sankyo, Inc; 2008.
16. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA. 1984;251(3):351-364.
17. Januvia (sitagliptin tablets) [package insert]. Whitehouse Station, NJ: Merck and Co. Inc; 2008.
18. Prandin (repaglinide tablets) [package insert]. Princeton, NJ: Novo Nordisk, Inc; 2006.
19. Starlix (nateglinide tablets) [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corp; 2008.
20. Micronase (glyburide tablets) [package insert]. New York, NY: Pfizer Inc; 2009.
21. Amaryl (glimepiride tablets) [package insert]. Parsippany, NJ: Aventis Pharmaceuticals, Inc; 2001.
22. Glucotrol XL (glipizide extended release tablets) [package insert]. New York, NY: Pfizer, Inc; 2009.
23. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837-853.
24. Meinert CL, Knatterud GL, Prout TE, Klimt CR. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes II Mortality results. Diabetes. 1970;19(suppl):789-830.
25. Avandia (rosiglitazone maleate tablets) [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2008.
26. Actos (pioglitazone hydrochloride tablets) [package insert]. Deerfield, IL: Takeda Pharmaceuticals America, Inc; 2007.
27. Nissen SE, Volski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356(24):2457-2471. (Pubitemid 46919772)
28. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366(9493):1279-1289. (Pubitemid 41416583)
29. American College of Endocrinology/American Association of Clinical Endocrinologists Diabetes Road Map Task Force. Road maps to achieve glycemic control in type 2 diabetes mellitus. 2008.
30. Joslin Diabetes Center and Joslin Clinic. Clinical guideline for pharmacological management of type 2 diabetes. 2009.
31. Ong KL, Cheung BM, Wong LY, Wat NM, Tan KC, Lam KS. Prevalence, treatment, and control of diagnosed diabetes in the U.S. National Health and Nutrition Examination Survey 1999-2004. Ann Epidemiol. 2008;18(3):222-229.
32. Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA. 2004;29l(3):335-342.
33. Turner RC, Cull CA, Frighi V, Holman RR; UK Prospective Diabetes Study (UKPDS) Group. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA. 1999;281(21):2005-2012.
34. Bagust A, Beale S. Deteriorating beta-cell function in type 2 diabetes: a long-term model. QJM. 2003;96(4):28l-288. (Pubitemid 36432387)
35. Pitocco D, Valle D, Rossi A, Gentilella R. Unmet needs among patients with type 2 diabetes and secondary failure to oral anti-diabetic agents. J Endocrinol Invest. 2008;31(4):371-379. (Pubitemid 351796626)
36. Joy SV. Clinical pearls and strategies to optimize patient outcomes. Diabetes Educ. 2008;34(suppl 3):54S-59S.
37. Rubin RR. Adherence to pharmacologic therapy in patients with type 2 diabetes mellitus. Am J Med. 2005;118(suppl 5A):27S-34S. (Pubitemid 40585813)
38. Schmindiel JA, Uratsu CS, Karter AJ, et al. Why don't diabetes patients achieve recommended risk factor targets? Poor adherence versus lack of treatment intensification. J Gen Intern Med. 2008;23(5):588-594.
39. Bolen SD, Bricker E, Samuels TA, et al. Factors associated with intensification of oral diabetes medications in primary care provider-patient dyads: a cohort study. Diabetes Care. 2009;32(1):25-31.
40. Pan XR, Li GW, Hu YH, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care. 1997;20(4):537-544.
41. Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ. 2006;332(7533):73-78. (Pubitemid 43099245)
42. Orozco-Beltran D, Gil-Guillen VF, Quirce F, et al; Collaborative Diabetes Study Investigators. Control of diabetes and cardiovascular risk factors in patients with type 2 diabetes in primary care. The gap between guidelines and reality in Spain. Int J Clin Pract. 2007;61(6):909-9l5.
43. Gerich JE. Type 2 diabetes mellitus is associated with multiple cardiometabolic risk factors. Clin Cornerstone. 2007;8(3):53-68. (Pubitemid 351597784)
44. Haire-Joshu D, Glasgow RE, Tibba TL. Smoking and diabetes. Diabetes Care. 1999;22(11):1887-1898.
45. Al-Delaimy WK, Manson JE, Solomon CG, et al. Smoking and risk of coronary heart disease among women with type 2 diabetes mellitus. Arch Intern Med. 2002;162(3):273-279. (Pubitemid 34127404)
46. Adler AI, Stratton IM, Neil HA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ. 2000;321:412-419. (Pubitemid 30609443)
47. Ali YS, Linton MF, Fazio S. Targeting cardiovascular risk in patients with diabetes: management of dyslipidemia. Curr Opin Endocrinol Diabetes Obes. 20013;15(2):142-146. (Pubitemid 351651727)
48. Collins R, Armitage J, Parish S, Sleigh P, Peto R; Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003;361(9374):2005-2016. (Pubitemid 36695042)
49. Goldberg RB, Mellies MJ, Sacks FM, et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators. Circulation. 1998;98(23):2513-2519.
50. Knopp RH, d'Emden M, Smilde JG, Pocock SJ. Efficacy and safety of atorvastatin in the prevention of cardiovaccular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN). Diabetes Care. 2006;29(7):1478-1485.
51. Sever PS, Poulter NR, Dahlof B, et al. Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial - lipid-lowering arm (ASCOT-LLA). Diabetes Care. 2005;28(5):1151-1157. (Pubitemid 40616627)
52. Shepherd J, Barter P, Carmena R, et al. Effect of lowering LDL cholesterol substantially below currently recommended 1evels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care. 2006;29(6):1220-1226. (Pubitemid 44125913)
53. Davidson MH, Dillon MA, Gordon B, et al. Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects. Arch Intern Med. 1999;159(16):1893-1900. (Pubitemid 29424709)
54. Insull W Jr, Toth P, Mullican W, et al. Effectiveness of colesevelam hydrochloride in decreasing LVL cholesterol in patients with primary hypercholesterolemia: a 24-week randomized controlled trial. Mayo Clin Proc. 2001;76(l0):971-982. (Pubitemid 32946008)
55. Hunninghake D, Insull W Jr, Toth P, Davidson D, Donovan JM, Burke SK. Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively. Atherosclerosis. 2001;158(2):407-416. (Pubitemid 32913651)
56. Knapp HH, Schrott H, Ma P, et al. Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia. Am J Med. 200l;l10(5):352-360. (Pubitemid 32248724)
57. Bays HE, Goldberg RB, Truitt KE, Jones MR. Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects. Arch Intern Med. 2008;168:1975-1983.
58. Fonseca VA, Rosenstock J, Wang AC, Truitt KE, Jones MR. Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy. Diabetes Care. 2008;31(8):1479-1484.
59. Goldberg RB, Fonseca VA, Truitt KE, Jones MR. Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy. Arch Intern Med. 2008;168(14):1531- 1540.
60. Wolffenbuttel BH, Sels JP, Rondas-Colbers GJ, Menheere PP. Prognostic factors for successful insulin therapy in subjects with type 2 diabetes. Neth J Med. l999;54(2):63-69. (Pubitemid 29073640)
61. Gavin LA, Barth J, Arnold D, Shaw R. Troglitazone add-on therapy to a combination of sulfonylureas plus metformin achieved and sustained effective diabetes control. Endocr Pract. 2000;6(4):305-310.
62. Fujioka K, Seaton TB, Rowe F, et al; Sibutramine/Diabetes Clinical Study Group. Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2000;2(3):175-187.
63. Igarashi M, Jimbu Y, Kimura M, Hirata A, Yamaguchi H, Tominaga M. Effect of pioglitazone on atherogenic outcomes in type 2 diabetic patients: a comparison of responders and non-responders. Diabetes Res Clin Pract. 2007;77(3):389-398. (Pubitemid 47211336)
64. Spann SJ, Nutting PA, Galliher JM, et al. Management of type 2 diabetes in the primary care setting: a practice-based research network study. Ann Fam Med. 2006;4(1):23-31. (Pubitemid 43243909)
65. Bertoni AG, Clark JM, Feeney P, et al; Look AHEAD Research Group. Suboptimal control of glycemia, blood pressure, and LDL cholesterol in overweight adults with diabetes: the Look AHEAD Study. J Diabetes Complications. 2008;22(1):1-9.
66. Barnett AH. The importance of treating cardiometabolic risk factors in patients with type 2 diabetes. Diab Vasc Dis Res. 2008;5(1):9-l4.
67. Meeuwisse-Pasterkamp SH, van der Klauw MM, Wolffenbuttel BH. Type 2 diabetes mellitus: prevention of macrovascular complications. Espert Rev Cardiovasc Ther. 2008;6(3):323-341.